| BACKGROUND: The etiology of breast cancer is uncertain yet, but the occurrence of it is correlated with age and the time Exposed to risk factor. The recent epidemiological survey of breast cancer shows: the main risk factor of breast cancer in our country at present is benign breast disease history, psyche stimulation, lactation history, neoplasm family history, menstrual cycle, the age of menarche, parity, the age of primiparity, weight in order. The estimate value of relative risk is maximal in benign those who have breast disease history and minimal in weight. The epidemiology behavior of breast cancer shows: the incidence rate rise year by year, the age tend to younger, and it's incidence rate has been the first one among malignant tumor of female. With the progress in understanding the biology behavior of breast cancer and the expansion of many cosmically randomized control clinical trial and the report of its outcome, we have had cognizance of that breast cancer is a systemic disease from initiation. Early distant metastasis occurs easily which lead to the failure of treatment and the death of patients. So earlier period diagnoses and perfect early colligation therapeutics has become the standard mode of breast cancer. Rational colligation therapeutics is the sticking point of the treatment of breast cancer and can bring better life quality and longer lifetime to patients. Systemic therapy plays an important role in colligation therapeutics, and it's a focus of clinical investigation presently. Systemic therapy is the only choice to those who are inoperable, recurrent or metastatic to obtain clinical response or cure. At present, chemotherapy is the most efficiency therapy and is most widely used in clinic, followed by endocrine therapy, immune therapy, Chinese traditional medicine therapy et al. Butchemotherapy also has many side-effects, different chemotherapy scheme has different side-effects, such as Bone marrow depression Gastrointestinal tract ill effects Alopecia > allergic reaction, heart toxicity et al. With the developing of medicine technology, some of the side effects have been lessened, but still affect the life quality of patients.At present the chemotherapy scheme of breast cancer inland usually follows that from overseas, such as CMF> CAF, AC et al. As these schemes killing the tumor effectively, they also damnify the function of immune system, sequentially, impact the life quality of patients badly. Chinese traditional medicine has some curative effect on carcinoma, and a series of outcome has been acquired. How to find out its molecular biology mechanism and apply it correctly to the treatment of malignant tumor for perfect clinical effect is what we should do.The treatment of digestive system and respiratory tract tumor by norcantharidin astragalus and ginsenoside has been reported. But we have not find out such report about breast cancer yet. This study is to investigate the mechanism of effect to breast cancer by norcantharidin astragalus and ginsenoside. We observed their damaging effect to tumor tissue and evaluated the influence to immune system. Furthermore we studied the inhibitory effect to the growth of MDA-MB-231 cell and the inducement effect to the apoptosis of MDA-MB-231 cell.Section 1 The clinical study on neoadjuvant chemotherapy treatment of breast cancer by norcantharidin astragalus and ginsenoside.Objective: To study the influence to immune system and the inhibitory effect to tumor by norcantharidin astragalus and ginsenoside in the neoadjuvant chemotherapy of local advanced breast cancer.Methods: From February 2001 to December 2003, 60 cases LABC patients were divided into two groups randomly. The test group was treated with standard CMF scheme plus norcantharidin astragalus and ginsenoside 100 ml; the control group was treated with standard CMF scheme plus NS. The immune markers such as T lymphocyte subpopulations and the activity of natural killer cells were studied. The difference of tumor microvessel density and apoptosis index (AI) between two groups was compared.RESULT: The immune markers of test group enhanced or retain stable. The MVD of test group is obviously lower than control group, and AI is higher than control group.Conclusion: The injection can redress the destruction effect to immune system remarkably in the neoadjuvant chemotherapy of breast cancer, and protect the function of immune system, relieve the side effect of chemotherapy, made the patients more tolerant to the operation, amelioration the quality of life. And it can suppress tumor angiogenesis, assist the toxic action of chemotherapy medicine, promote the putrescence of tumor tissue, enhance the effect of chemotherapy. It has good effect in combine with CMF scheme.Section 2 The experimental study on influence to proliferation of MDA-MB-231 cell by norcantharidin astragalus and ginsenoside.OBJECTIVE: Observe the influence to apoptosis of MDA-MB-231 cell by norcantharidin astragalus and ginsenoside and investigate its mechanism.METHOD: MDA-MB-231 cell were treated with lOug/ml 30ug/ml 60ug/mlinjection for 12 24 48 72 hours, respectively. Morphological changes were examined with microscope; cell proliferation was evaluated by MTT assay, distribution of cell cycle, rate of cell apoptosis were determined by flow cytometry.RESULT: The injection has marked inhibitory effect on proliferation of MDA-MB-231 cells by arresting its cell cycle in G2/M phase, and it can induce the apoptosis of tumor cells.CONCLUSION: Norcantharidin astragalus and ginsenoside can inhibit proliferation and induce apoptosis in MDA-MB-231 cells.
|
PDF Full Text Request